UNSPSC 51373460: Codeine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373460 Codeine/pyrilamine, a Commodity code, represents pharmaceutical products that state and local governments procure for public health and emergency response programs. Recent opportunities show that this code encompasses both prescription pharmaceuticals and over-the-counter medications distributed through authorized wholesale channels to support community health initiatives, emergency medical services, and institutional healthcare needs. Issuing bodies include county health departments, state purchasing offices, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, and county-level health agencies such as Seminole County, Florida represent the primary buyer types, with cooperative vehicles enabling smaller jurisdictions to leverage volume pricing and standardized supplier relationships.

Geographic activity centers on the Upper Midwest and Southeast, with documented recent solicitations from Minnesota and Florida. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Minnesota Department of Administration issued an RFP (S1070000015802) through MMCAP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) with pricing weighted at 75 percent of evaluation criteria. Both procurements require cGMP certification, compliance with the Drug Supply Chain Security Act, and E-Verify eligibility, with no explicit set-aside designations noted in the available documentation.